Reset filter
Palabras clave
Helsesjekk ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

789 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Visit V6_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V6 (Day 196 + - 14)

- 27/9/21 - 1 formulario, 5 itemgroups, 35 items, 1 idioma
Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, medication Demand
Study part: Visit V6 (Day 196 + - 14). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Vital Signs Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Vital Signs Follow- Up (Visit 10)

- 27/9/21 - 1 formulario, 1 itemgroup, 10 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Vital Signs Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Visite 8 (Woche 24) TMP001 Multiple Sclerosis NCT02686788 - Visite 8 (Woche 24)

- 27/9/21 - 1 formulario, 11 itemgroups, 57 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 8 (Woche 24). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 7 (Woche 20) TMP001 Multiple Sclerosis NCT02686788 - Visite 7 (Woche 20)

- 27/9/21 - 1 formulario, 11 itemgroups, 57 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 7 (Woche 20). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Baseline Visite (Visite 2/ Woche 0) TMP001 Multiple Sclerosis NCT02686788 - Baseline Visite (Visite 2/ Woche 0)

- 27/9/21 - 1 formulario, 10 itemgroups, 53 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, Comorbidity; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Inclusion criteria; exclusion criteria, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Baseline Visite (Visite 2/ Woche 0). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 5 (Woche 12) TMP001 Multiple Sclerosis NCT02686788 - Visite 5 (Woche 12)

- 27/9/21 - 1 formulario, 11 itemgroups, 57 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 5 (Woche 12). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 6 (Woche 16) TMP001 Multiple Sclerosis NCT02686788 - Visite 6 (Woche 16)

- 27/9/21 - 1 formulario, 11 itemgroups, 57 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 6 (Woche 16). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 3 (Woche 4) TMP001 Multiple Sclerosis NCT02686788 - Visite 3 (Woche 4)

- 27/9/21 - 1 formulario, 11 itemgroups, 57 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 3 (Woche 4). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 4 (Woche 8) TMP001 Multiple Sclerosis NCT02686788 - Visite 4 (Woche 8)

- 27/9/21 - 1 formulario, 11 itemgroups, 57 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 4 (Woche 8). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

12- Lead ECG, Telemetry, Holter Monitoring Pazopanib Macular Degeneration MD1103367 - 12- Lead ECG, Telemetry, Holter Monitoring

- 27/9/21 - 1 formulario, 3 itemgroups, 18 items, 1 idioma
Itemgroups: 12 Lead ECG, Telemetry, 24 Hour Holter Monitoring
Study part: 12- Lead ECG, Telemetry, Holter Monitoring. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

medical examination SHIP-Trend-0 blood pressure

- 27/9/21 - 1 formulario, 1 itemgroup, 23 items, 2 idiomas
Itemgroup: blood pressure
blood pressure form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.MEX.PHYSEXAM.BLOODPRE. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Vital Signs (VS) Screening Pazopanib Macular Degeneration MD1103367 - Vital Signs (VS) Screening

- 20/9/21 - 1 formulario, 2 itemgroups, 14 items, 1 idioma
Itemgroups: vital sign measurement supine, Vital signs measurements
Study part: Vital Signs (VS) Screening. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial